The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Open accessAbstract
Epithelial–mesenchymal transition (EMT) is known to play an important role in cancer progression, metastasis and drug resistance. Although there are controversies surrounding the causal relationship between EMT and cancer metastasis, the role of EMT in cancer drug resistance has been increasingly recognized. Numerous EMT-related signaling pathways are involved in drug resistance in cancer cells. Cells undergoing EMT show a feature similar to cancer stem cells (CSCs), such as an increase in drug efflux pumps and anti-apoptotic effects. Therefore, targeting EMT has been considered a novel opportunity to overcome cancer drug resistance. This review describes the mechanism by which EMT contributes to drug resistance in cancer cells and summarizes new advances in research in EMT-associated drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Non-coding RNAs and cancer: microRNAs and beyond
Raia, R. M., & Calin, G. A. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e5 · Cited by 3,382
Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., & García de Herreros, A. (2000) · Nature Cell Biology · doi:10.1038/35000034 · Cited by 2,666
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
EMT, the cytoskeleton, and cancer cell invasion
Yilmaz, M., & Christofori, G. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9169-0 · Cited by 1,788
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., & Brabletz, T. (2008) · EMBO reports · doi:10.1038/embor.2008.74 · Cited by 1,722
Signaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721
Epithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,699
An Overview of Epithelio-Mesenchymal Transformation
Hay, E. D. (1995) · Cells Tissues Organs · doi:10.1159/000147748 · Cited by 1,567
The Two-Handed E Box Binding Zinc Finger Protein SIP1 Downregulates E-Cadherin and Induces Invasion
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D., & van Roy, F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00260-x · Cited by 1,394
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.022 · Cited by 1,071
Liu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-Trevino, R., Shang, L., McDermott, S. P., Landis, M. D., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.11.009 · Cited by 1,053
Timmerman, L. A., Grego-Bessa, J., Raya, A., Bertrán, E., Pérez-Pomares, J. M., Díez, J., Aranda, S., Palomo, S., McCormick, F., Izpisúa-Belmonte, J. C., et al. (2004) · Genes & Development · doi:10.1101/gad.276304 · Cited by 985
Ocaña, O. H., Córcoles, R., Fabra, Á., Moreno-Bueno, G., Acloque, H., Vega, S., Barrallo-Gimeno, A., Cano, A., & Nieto, M. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.012 · Cited by 973
Moustakas, A., & Heldin, C.-H. (2005) · Journal of Cell Science · doi:10.1242/jcs.02554 · Cited by 958
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., Gallick, G. E., Logsdon, C. D., McConkey, D. J., & Choi, W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2819 · Cited by 863
Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y., & Johnson, K. R. (2008) · Journal of Cell Science · doi:10.1242/jcs.000455 · Cited by 767
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753
Bremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., Camps, C., Marinez, I., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f8a1bd · Cited by 691
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
Wnt-dependent Regulation of the E-cadherin Repressor Snail
Yook, J. I., Li, X.-Y., Ota, I., Fearon, E. R., & Weiss, S. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413878200 · Cited by 445
Pérez-Moreno, M. A., Locascio, A., Rodrigo, I., Dhondt, G., Portillo, F., Nieto, M. A., & Cano, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100827200 · Cited by 440
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
Saxena, M., Stephens, M. A., Pathak, H., & Rangarajan, A. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.61 · Cited by 408
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Natarajan, K., Xie, Y., Baer, M. R., & Ross, D. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.002 · Cited by 405
EMT and MET in Metastasis: Where Are the Cancer Stem Cells?
Brabletz, T. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.009 · Cited by 403
Haslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., Weberpals, J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance
Siebzehnrubl, F. A., Silver, D. J., Tugertimur, B., Deleyrolle, L. P., Siebzehnrubl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302827 · Cited by 381
Early events in cell adhesion and polarity during epithelial-mesenchymal transition
Huang, R. Y.-J., Guilford, P., & Thiery, J. P. (2012) · Journal of Cell Science · doi:10.1242/jcs.099697 · Cited by 369
McConkey, D. J., Choi, W., Marquis, L., Martin, F., Williams, M. B., Shah, J., Svatek, R., Das, A., Adam, L., Kamat, A., et al. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9194-7 · Cited by 368
Hepatocyte growth factor induces cell scattering through MAPK/Egr‐1‐mediated upregulation of Snail
Grotegut, S., von Schweinitz, D., Christofori, G., & Lehembre, F. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601213 · Cited by 363
Biddle, A., Liang, X., Gammon, L., Fazil, B., Harper, L. J., Emich, H., Costea, D. E., & Mackenzie, I. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1059 · Cited by 356
Kaimori, A., Potter, J., Kaimori, J.-Y., Wang, C., Mezey, E., & Koteish, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700998200 · Cited by 355
Complexities of TGF-β Targeted Cancer Therapy
Connolly, E. C., Freimuth, J., & Akhurst, R. J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4564 · Cited by 345
Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., & Sarkar, F. H. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.07.001 · Cited by 343
Yoo, Y. A., Kang, M. H., Lee, H. J., Kim, B.-H., Park, J. K., Kim, H. K., Kim, J. S., & Oh, S. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1338 · Cited by 340
P-Glycoproteins and Multidrug Resistance
Bellamy, W. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001113 · Cited by 319
Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J., & Derynck, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.095299 · Cited by 311
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284
Ward, A., Balwierz, A., Zhang, J. D., Küblbeck, M., Pawitan, Y., Hielscher, T., Wiemann, S., & Sahin, Ö. (2013) · Oncogene · doi:10.1038/onc.2012.128 · Cited by 280
Wu, Y., Ginther, C., Kim, J., Mosher, N., Chung, S., Slamon, D., & Vadgama, J. V. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0155-t · Cited by 268
Toden, S., Okugawa, Y., Jascur, T., Wodarz, D., Komarova, N. L., Buhrmann, C., Shakibaei, M., Boland, C. R., & Goel, A. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv006 · Cited by 248
Kim, H.-J., Litzenburger, B. C., Cui, X., Delgado, D. A., Grabiner, B. C., Lin, X., Lewis, M. T., Gottardis, M. M., Wong, T. W., Attar, R. M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01315-06 · Cited by 241
Meidhof, S., Brabletz, S., Lehmann, W., Preca, B., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404396 · Cited by 229
Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer
Munoz, M., Henderson, M., Haber, M., & Norris, M. (2007) · IUBMB Life · doi:10.1080/15216540701736285 · Cited by 226
Implication of microRNAs in drug resistance for designing novel cancer therapy
Sarkar, F. H., Li, Y., Wang, Z., Kong, D., & Ali, S. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.02.001 · Cited by 215
Vazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Del Barco, S., Martin-Castillo, B., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.18.13131 · Cited by 205
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 201
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185
Screening therapeutic EMT blocking agents in a three-dimensional microenvironment
Aref, A. R., Huang, R. Y.-J., Yu, W., Chua, K.-N., Sun, W., Tu, T.-Y., Bai, J., Sim, W.-J., Zervantonakis, I. K., Thiery, J. P., et al. (2013) · Integr. Biol. · doi:10.1039/c2ib20209c · Cited by 183
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Uramoto, H., Iwata, T., Onitsuka, T., Shimokawa, H., Hanagiri, T., & Oyama, T. (2010) · PubMed · Cited by 171
Chou, C.-C., Lee, K.-H., Lai, I.-L., Wang, D., Mo, X., Kulp, S. K., Shapiro, C. L., & Chen, C.-S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0135 · Cited by 170
Soucheray, M., Capelletti, M., Pulido, I., Kuang, Y., Paweletz, C. P., Becker, J. H., Kikuchi, E., Xu, C., Patel, T. B., Al‐Shahrour, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0377 · Cited by 166
Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Chang, T.-H., Tsai, M.-F., Su, K.-Y., Wu, S.-G., Huang, C.-P., Yu, S.-L., Yu, Y.-L., Lan, C.-C., Yang, C.-H., Lin, S.-B., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1440oc · Cited by 163
Kühnle, M., Egger, M. E., Müller, C., Mahringer, A., Bernhardt, G., Fricker, G., König, B., & Buschauer, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8013822 · Cited by 158
Dalton, W. S., Crowley, J. J., Salmon, S., Grogan, T. M., Laufman, L. R., Weiss, G. R., & Bonnet, J. D. (1995) · Cancer · Cited by 158
Epithelial-mesenchymal transition and drug resistance in breast cancer (Review)
Huang, J., Li, H., & Ren, G. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3084 · Cited by 156
miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin
Zhu, X., Shen, H., Yin, X., Long, L., Xie, C., Liu, Y., Hui, L., Lin, X., Fang, Y., Cao, Y., et al. (2015) · Oncogene · doi:10.1038/onc.2015.84 · Cited by 156
Qu, C., Zhang, W., Zheng, G., Zhang, Z., Yin, J., & He, Z. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1845-x · Cited by 152
Chiu, W., Huang, Y.-F., Tsai, H.-Y., Chen, C., Chang, C.-H., Huang, S.-C., Hsu, K., & Chou, C.-Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2957 · Cited by 146
Guan, J., Zhang, H., Wen, Z., Gu, Y., Cheng, Y., Sun, Y., Zhang, T., Jia, C., Lu, Z., & Chen, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.006 · Cited by 146
Li, J., Wang, Y., Song, Y., Fu, Z., & Yu, W. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-193 · Cited by 139
Biddle, A., Gammon, L., Liang, K. X., Costea, D. E., & Mackenzie, I. C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.01.007 · Cited by 137
Nan, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1197 · Cited by 129
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 127
Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, M., Papaccio, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3319 · Cited by 122
Zhao, Z., Cheng, X., Wang, Y., Han, R., Li, L., Xiang, T., He, L., Long, H., Zhu, B., & He, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095884 · Cited by 115
Liao, H., Bai, Y., Qiu, S., Zheng, L., Huang, L., Liu, T., Wang, X., Liu, Y., Xu, N., Yan, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3563 · Cited by 113
MiR‐489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway
Jiang, L., He, D., Yang, D., Chen, Z., Pan, Q., Mao, A., Cai, Y., Li, X., Xing, H., Shi, M., et al. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.024 · Cited by 112
Yang, Q., Wang, Y., Lu, X., Zhao, Z., Zhu, L., Chen, S., Wu, Q., Chen, C., & Wang, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.3065 · Cited by 108
Xie, M., He, C.-S., Wei, S., & Zhang, L. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.007 · Cited by 107
Cai, J., Tian, A.-X., Wang, Q.-S., Kong, P.-Z., Du, X., Li, X., & Feng, Y.-M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.001 · Cited by 104
Xu, L., ZHANG, L., HU, C., Liang, S., Fei, X., Yan, N., Zhang, Y., & Zhang, F. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3337 · Cited by 104
Zhou, Y., Liang, C., Xue, F., Chen, W., Zhi, X., Feng, X., Bai, X., & Liang, T. (2015) · Oncotarget · doi:10.18632/oncotarget.3585 · Cited by 101
Tan, X., Fu, Y., Chen, L., Lee, W., Lai, Y., Rezaei, K., Tabbara, S. O., Latham, P. S., Teal, C. B., Man, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6344 · Cited by 101
Yoshida, T., Song, L., Bai, Y., Kinose, F., Li, J., Ohaegbulam, K. C., Muñoz-Antonia, T., Qu, X., Eschrich, S. A., Uramoto, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147344 · Cited by 99
Zhang, R., Zhang, P., Wang, H., Hou, D., Li, W., Xiao, G., & Li, C. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0249-0 · Cited by 98
Probing the Fifty Shades of EMT in Metastasis
Li, W., & Kang, Y. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.01.001 · Cited by 98
Han, D., Wu, G., Chang, C. F., Zhu, F., Xiao, Y., Li, Q., Zhang, T., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5723 · Cited by 97
Ma, J., Fang, B., Zeng, F., Ma, C., Pang, H., Cheng, L., Shi, Y., Wang, H., Yin, B., Xia, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2714 · Cited by 96
Li, J., Liu, H., Yu, J., & Yu, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3356 · Cited by 96
Sui, H. X., Zhu, L., Deng, W., & Li, Q. (2014) · Oncology Research and Treatment · doi:10.1159/000367802 · Cited by 87
Zhao, Z., Zhang, L., Yao, Q., & Tao, Z. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.73 · Cited by 86
Chua, K. N., Sim, W.-J., Racine, V., Lee, S.-Y., Goh, B. C., & Thiery, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033183 · Cited by 85
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
Nishijima, N., Seike, M., Soeno, C., Chiba, M., Miyanaga, A., Noro, R., Sugano, T., Matsumoto, M., Kubota, K., & Gemma, A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3331 · Cited by 82
Zhou, Z., Zhang, L., Xie, B., Wang, X., Yang, X., Ding, N., Zhang, J., Liu, Q., Tan, G., Feng, D., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.008 · Cited by 81
Qin, G., Xu, F., Qin, T., Zheng, Q., Shi, D., Xia, W., Tian, Y., Tang, Y., Wang, J., Xiao, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5993 · Cited by 81
Namba, T., Kodama, R., Moritomo, S., Hoshino, T., & Mizushima, T. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.172 · Cited by 75
Twist mediates an aggressive phenotype in human colorectal cancer cells
Deng, J., Zhang, W., Xu, X., Zhang, F., Tao, W., Ye, J., & Ge, W. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3342 · Cited by 71
Bai, J., Tu, T.-Y., Kim, C., Thiery, J. P., & Kamm, R. D. (2015) · Oncotarget · doi:10.18632/oncotarget.5464 · Cited by 70
Wen, Z., Feng, S., WEI, L., Wang, Z., Hong, D., & Wang, Q. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2383 · Cited by 69
Wang, R., Li, Y., Hou, Y., Yang, Q., Chen, S., Wang, X., Wang, Z., Yang, Y. F., Chen, C., Wang, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3193 · Cited by 56
Lancet, J. E., Baer, M. R., Durán, G. E., List, A. F., Fielding, R. M., Marcelletti, J. F., Multani, P. S., & Sikic, B. I. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.09.015 · Cited by 54
Transforming growth factor-β in in vivo resistance
Teicher, B. A., Holden, S. A., Ara, G., & Chen, G. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050435 · Cited by 52
Жао, Л., Liu, S., Che, X., Hou, K., Ma, Y., Li, C., Wen, T., Fan, Y., Hu, X., Liu, Y., et al. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2268 · Cited by 49
Busaranon, K., Phiboonchaiyanan, P. P., Sritularak, B., & Pithi Chanvorachote, B. (2015) · Journal of Natural Medicines · doi:10.1007/s11418-015-0931-7 · Cited by 48
Hermawan, A., Wagner, E., & Roidl, A. (2015) · Oncology Reports · doi:10.3892/or.2015.4509 · Cited by 48
Existing drugs and their application in drug discovery targeting cancer stem cells
Lv, J., & Shim, J. S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0628-1 · Cited by 29
Self-citationAnimal Models and the Tumor Microenvironment: Studies of Tumor–Host Symbiosis
Lindner, D. J. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.004 · Cited by 23
Cited by
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance
Mashouri, L., Yousefi, H., Aref, A. R., Ahadi, A. M., Molaei, F., & Alahari, S. K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0991-5 · Cited by 1,363
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Metadata
- Authors
- Du, B., & Shim, J.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2016-07-22
- Volume
- 21
- Issue
- 7
- Pages
- 965
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2500192509
- Cited by
- 807
- References
- 120
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.